Microplasmin Administered Via the Trellis-8 Infusion System for Treatment of Acute Iliofemoral DVT (MAX-DVT)
This study has been terminated.
(Sponsor's decision to not pursue uPLi for vascular conditions including DVT.)
Sponsor:
ThromboGenics
Collaborator:
Bacchus Vascular
Information provided by:
ThromboGenics
ClinicalTrials.gov Identifier:
NCT00428129
First received: January 26, 2007
Last updated: November 25, 2008
Last verified: November 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A single centre, single-arm study to evaluate safety and efficacy of microplasmin administration via the Trellis-8 Infusion System in patients with acute iliofemoral DVT
| Condition | Intervention | Phase |
|---|---|---|
|
Deep Vein Thrombosis |
Drug: microplasmin |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Open Label Clinical Trial of Microplasmin Administered Via the Trellis-8 Infusion System for the Treatment of Acute Iliofemoral Deep Vein Thrombosis |
Resource links provided by NLM:
MedlinePlus related topics:
Deep Vein Thrombosis
Drug Information available for:
Ocriplasmin
U.S. FDA Resources
Further study details as provided by ThromboGenics:
Primary Outcome Measures:
- Treatment success - treated segment has < 25% residual thrombus AND flow is present following administration of microplasmin [ Time Frame: During intervention procedure ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Grade of lysis [ Time Frame: Upon completion of procedure ] [ Designated as safety issue: No ]
- Limb patency [ Time Frame: Baseline, 48h post procedure, Day-7 and Day-30 ] [ Designated as safety issue: No ]
- Target limb reintervention [ Time Frame: Day-7 and Day-30 ] [ Designated as safety issue: No ]
- Clinical outcomes [ Time Frame: Baseline, 48h post procedure, Day-7 and Day-30 ] [ Designated as safety issue: No ]
| Enrollment: | 6 |
| Study Start Date: | March 2007 |
| Study Completion Date: | October 2008 |
| Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 |
Drug: microplasmin
20mg with Trellis-8 15cm Treatment length 40mg with Trellis-8 30cm Treatment length
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria include:
- Patients with radiographically-confirmed acute proximal DVT
Exclusion Criteria include:
- Isolated calf or popliteal vein DVT, based on duplex ultrasound
- Thrombus involving the inferior vena cava (IVC)
- Proximal (e.g. cranial) aspect of thrombus cannot be adequately assessed to level of the iliac veins or inferior vena cava, based on duplex ultrasound.
- Cannot traverse the target vessel segment with guidewire
- Symptomatic pulmonary embolism is present at time of presentation
- Documented history of prior DVT in target extremity
- History of anticoagulants administered for > 30 days for undocumented/ unclear reason (e.g. for reasons other than presence of mechanical cardiac valve, atrial fibrillation, etc.)
- Documented history of thrombophilic disorder, with diagnosis established via previous objective testing (e.g. familial screening for thrombophilia).
- Cannot receive standard secondary prevention pharmacotherapy [i.e. heparin or LMWH and vitamin K antagonists (VKA)] due to contraindications to anticoagulation [e.g. known bleeding diathesis, thrombocytopenia (platelets < 100,000 mm3), heparin induced thrombocytopenia (HIT), known allergy to heparin or warfarin]
- Absolute contraindication to thrombolytic therapy
- Previous central nervous system haemorrhage
- Life expectancy less than 1 year, due to other comorbid condition.
- Previous intervention in target limb to address venous thrombus.
- Target limb has chronic venous insufficiency of C4 or greater severity
- Acute or chronic symptomatic musculoskeletal condition in target limb (e.g. trauma, fracture, severe arthritis).
- Documented patent foramen ovale or other right-to-left cardiac shunt.
- Absolute contraindication to contrast media or renal insufficiency (baseline creatinine >2.0 mg/dL).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00428129
Locations
| Ireland | |
| Section of Interventional Radiology, Department of Radiology, University College Hospital, Newcastle Road | |
| Galway, Co Galway, Ireland | |
Sponsors and Collaborators
ThromboGenics
Bacchus Vascular
Investigators
| Principal Investigator: | Gerard O'Sullivan, MD | Section of Interventional Radiology, Department of Radiology, University College Hospital, Newcastle Road, Galway |
More Information
No publications provided
| Responsible Party: | Sophie Gunn, ThromboGenics |
| ClinicalTrials.gov Identifier: | NCT00428129 History of Changes |
| Other Study ID Numbers: | TG-M-005 |
| Study First Received: | January 26, 2007 |
| Last Updated: | November 25, 2008 |
| Health Authority: | Ireland: Irish Medicines Board |
Keywords provided by ThromboGenics:
|
Acute Iliofemoral Deep Vein Thrombosis |
Additional relevant MeSH terms:
|
Thrombosis Venous Thrombosis Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on June 18, 2013